In the United Kingdom and in the United States the geographical distribution of certain diseases, including some cancers, correlates positively with the degree of industrialisation and hence with the extent of exposure to toxic environmental chemicals.' Nevertheless, attempts to associate specific adverse health effects with exposure to specific toxic chemicals are beset with numerous difficulties. One of the more vexing is that such diseases may not appear until many years after the initial exposure.
A second problem is the extreme diversity of chemical exposure; subjects are often exposed to a broad array of potentially harmful chemicals, rarely just one or two. For many environmental chemicals we do not know the precise sources, prevalence, concentrations, and time course of exposure. With respect to the chemicals themselves, we often remain uncertain of the precise health effects of impurities, contaminants, or environmentally induced alterations in structure. Nor do we know the precise dose of a specific chemical that can produce in each person different pollutant related diseases. Dose response curves for toxicity from environmental chemicals have not been established for different cells of the same tissue, different tissues, different individuals, and different populations. Such information, though presently unobtainable in man, would be most useful in estimating the extent of interindividual variation in susceptibility to toxicity from environmental chemicals.
A further complication is that at different times even the same person becomes more or less susceptible to toxicity from environmental chemicals. Such temporal fluctuations in susceptibility derive from the fact that toxicological sequelae may be greatly influenced by alterations in dynamically interacting host factors. These host factors include age, diet, weight, general health, functional status of various organs, immunological competence, cigarette smoking, ethanol ingestion, and exposure to other xenobiotics. Expression of these host factors may be greatly affected by genetic constitution, behaviour, and environment, all of which also interact in complex, changing ways.
A third problem is the heterogeneity of exposed subjects with respect to critical host factors-for instance, genetic constitution-as well as several other factors Qualitative and quantitative differences among subjects in pathways of drug metabolism are believed to be engaged in the regulation and control of such tissue damage. Thus genetic differences among subjects in the enzymes that regulate these pathways render some subjects particularly susceptible to toxicity from different reactive metabolites. Recent work has shown multiple molecular forms or isozymes of cytochrome P-450. Although the precise number of these genetically distinct forms has not been established, thus far 20 such isozymes have been isolated and characterised. These exceedingly heterogeneous isozymes exhibit broad, overlapping substrate specificity and are induced by different chemicals. '2 Twin and family studies showed genetic control of large differences among normal subjects in the drug metabolising capacity of these proteins.2 6 The extent of this variation ranges from fourfold to 40-fold, depending on the subjects and drugs selected for investigation. A specific example of the toxicological consequences of genetic differences in drug metabolising capacity is the 40-fold range among normal subjects in the capacity to metabolise chemical carcinogens by a specific cytochrome P-450 dependent isozyme, aryl hydrocarbon hydroxylase (AHH). '3 14 High activities are associated with lung carcinomas but not with familial susceptibility to childhood leukaemia.'3 14 Genetic control of large differences in inducibility of AHH activity have been shown. [13] [14] [15] [16] Presumably, raised AHH activity would produce higher concentrations of toxic reactive intermediates on exposure to polycyclic aromatic hydrocarbons. Reactive intermediates increase chances for covalent binding to DNA, thereby initiating a sequence of events that requires many years to unfold and eventually manifests as a neoplasm.
Another pharmacogenetic condition with implications for susceptibility to toxic industrial chemicals is the polymorphism of the hepatic enzyme Nacetyltransferase. Individuals autosomally recessive for the gene that controls this enzyme conjugate several drugs much more slowly than rapid acetylators. Drugs acetylated by this enzyme include isoniazid, phenelzine, hydralazine, sulphapyridine, and procainamide. Given the same dosing regimen, subjects with the slow phenotype have higher concentrations of these drugs in their bodies than subjects with the rapid phenotype. Therefore, slow acetylators would tend to be more susceptible than rapid acetylators to toxicity from chronic administration of these drugs due to drug accumulation. For isoniazid, such toxicity is manifested as polyneuritis from pyridoxine deficiency; isoniazid competes with pyridoxine for cellular uptake and utilisation.
Subjects with the slow acetylator phenotype were hypothesised to have an increased risk of bladder can-508 cer induced by aromatic amines, since such subjects would have a reduced capacity to detoxify benzidine and arylamines through conjugation."7 Arylamines require metabolic activation to initiate carcinogenesis. ' 8 Such activation occurs through a hepatic cytochrome P-450 isozyme that hydroxylates the arylamine. In slow acetylators more arylamine would be expected to accumulate secondary to reduced rates of acetylation and hence become available for hydroxylation. Once formed, the hydroxylamine is acetylated to form N-hydroxylamine-N-glucuronide; it is speculated that this metabolite decomposes in the bladder to a highly reactive arylnitrenium ion that combines with nucleic acid to initiate carcinogenesis."8 This illustrates the important principle that a genetically controlled block in a metabolic pathway can cause a shift to an alternative, parallel pathway that yields a more toxic final product.
In 22 were slow acetylators. '9 20 Furthermore, as the rate of acetylation declined among these 22 slow acetylators the invasiveness of the bladder tumours increased. '9 20 The final example to be discussed concerns the human leukocyte antigens (HLA) and their association with increased and decreased risk of certain immunological diseases as well as drug toxicity. The HLA genetic determinants on a single chromosome constitute a haplotype. Every person has two haplotypes, one inherited from each parent. At least four closely linked loci, only a few centimorgans apart on the short arm of human chromosome 6, control the synthesis of antigens on the surface of leukocytes. Because of their close linkage, the specific genes at these four loci only rarely separate through crossover between homologous chromosomes during meiosis.
Of interest is the extreme genetic heterogeneity of these four loci, more than 100 alleles having been identified, theoretically enabling more than 1 000 000 different phenotypes. HLA loci and loci closely linked to them function in immune surveillance, protecting the body from several types of environmental assault. For example, these genes serve to combat viral and other pathogens and in the rejection response to foreign tissues.2' 22 Pertinent to this discussion, certain HLA haplotypes considerably increase susceptibility to disease associated with immunological impairment, initiated in some cases by environmental chemicals. These conditions include chronic active hepatitis, glomerulonephritis, ankylosing spondylitis, Reiter's syndrome, rheumatoid arthritis, and disseminated lupus erythematosus. In certain HLA haplotypes the risk of these disorders, all characterised by a derangement of normal immunological mechanisms, can increase by 40- With respect to adverse reactions to drugs, in patients with rheumatoid arthritis treated with sodium aurothiomalate adverse reactions, particularly proteinuria, occurred 32 times more frequently in the HLA-DR3 haplotype.26 Also in patients with rheumatoid arthritis agranulocytosis after levamisole was encountered much more frequently in subjects with the rare haplotype HLA-B27; in a report of three such patients tested eac!; possessed the B27 antigen.27 Hydralazine induced systemic lupus erythematosus occurred two to three times more often in hypertensive patients with HLA-DR4 haplotype who received the drug.28 Probably certain HLA haplotypes increase susceptibility to toxicity from industrial chemicals whereas other haplotypes may be associated with resistance to such toxicity.
These examples collectively illustrate progress in the rapidly expanding multidisciplinary fields of pharmacogenetics and ecogenetics. The future should disclose many more such conditions, particularly with the application of molecular approaches, including restriction fragment length polymorphisms. Even now, enough examples exist to show that toxicity to industrial chemicals develops not randomly or capriciously but rather due to diverse, often interacting, host factors, including genetically controlled susceptibility.
